15 October 2008: NorDiag has entered into two distribution agreements with German based Molzym GmbH [...]

NorDiag has entered into two distribution agreements with German based Molzym GmbH & Co KG covering Molzym`s molecular diagnostic products. The first agreement is geographically restrained to USA and Canada, while the second agreement covers the Nordic countries.

NorDiag has also entered into a collaboration agreement with Molzym, primarily with the purpose of integrating NorDiag`s magnetic bead based sample preparation chemistry and low throughput automation platform with Molzym`s molecular diagnostic products among others their SepsiTest(TM).

Sepsis (blood poisoning) is a systemic inflammation of the whole body ultimately leading to multiple organ dysfunctions and a mortality rate of 30-50%. SepsiTest(TM) is a novel PCR test for early and rapid diagnosis of sepsis. In less than four hours the broad-spectrum screening assay detects more than 345 relevant sepsis germs. Today`s conventional microbiological methods usually deliver results, on an average, only after 48 hours. SepsiTest(TM) received CE-IVD-marking according to European in-vitro diagnostic law and is now available for routine sepsis diagnostics.

- `We have chosen NorDiag due to their geographic presence, competence and position in the clinical diagnostic market`, says Molzym CEO Jan Detmers.

- `Growing revenues by taking in complementary products is a key element in our strategy going forward and the agreements with Molzym will be an important contributor in increasing volumes. We also intend to offer an OEM agreement for NorDiag`s products to Molzym, which will open for cross-sales and further increase revenues` says NorDiag CEO Mårten Wigstøl.

Contact:
CEO Mårten Wigstøl, Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

About Molzym:
Molzym GmbH & Co. KG, headquartered in Bremen, Germany, is a manufacturer of innovative products for molecular diagnostics. Based on proprietary, patented technologies Molzym`s kits and molecular diagnostic tools focus on the selective isolation of pathogen DNA from whole blood, robust and contamination-free PCR reagents and the molecular detection and identification of bacteria and fungi.
For more than 5 years, the world market of molecular diagnostics shows a compound annual growth rate of about 15%. Molzym regards itself as the technology and market leader in broad-spectrum molecular diagnostics. This market is believed to be one of the most important growth markets in diagnostics because of emerging infectious diseases and increasing antibiotic resistances around the world. For further information - www.sepsitest.com

Press contact:

CEO Dr. Jan Detmers, Phone: +49 421-2209-777-0

Read the Notice in Norwegian here